Alzheimers disease
Conditions
Interventions
Test food: A food containing 50 billion Bifidobacterium A1 sachets per test food or a placebo food: A food containing no bifidobacterium and containing 2000 mg of maltodextrin (both are manufactured b
Sponsors
Akatsu Hiroyasu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) MMSE-J (Nippon Bunka Kagakusha) score is 10-26 (2) Persons who have entered a facility related to Fukushimura Hospital and are attending Fukushimura Hospital if they are 50 years of age or older at the time of obtaining consent. (3) Persons who have been receiving medical treatment in the same environment for one month or more and are expected to receive medical treatment in the same environment in the future. (4) A person who has a substitute (guarantor at the time of admission / admission) when it is difficult to obtain document consent from the person
Exclusion criteria
Exclusion criteria: (1) Those who have difficulty ingesting orally (2) Persons with impaired consciousness (3) Those who have difficulty going to Fukushimura Hospital (4) Persons with hearing impairment that can affect psychological tests (5) Persons with MMSE-J (Nippon Bunka Kagakusha) score of 9 points or less or 27 points or more (6) When there are obvious lesions other than neurodegenerative diseases in the brain such as cerebrovascular accident, normal pressure hydrocephalus, subdural hematoma, and brain tumor by prior imaging examination (7) Persons with physical complications that may affect the study (8) Others who are judged to be inappropriate by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of change from baseline in ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) test from the time of registration as a neuropsychological test (at the end of the test: 48 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 Amount of change from baseline in the MMSE-J test from the time of registration as a neuropsychological test (at the end of the test: 48 weeks) 2 Behavioral Psychological Symptoms (BPSD) Evaluation (Amount of change from baseline in NPI-Q (Neuropsychiatric Inventory Questionnaire) from the time of enrollment (at the end of the study: 48 weeks)) 3 Volumetric quantitative evaluation by MRI 4 Changes in general test items, surrogate markers, and metabolite profile from the initial test to the end of the test (48 weeks) 5 Changes from initial examination of intestinal flora and metabolite profile to end of study (48 weeks) 6 Evaluation of fecal properties by Bristol Scale | — |
Contacts
Public ContactHiroyasu Akatsu
National Center for Geriatrics and Gerontology
Outcome results
None listed